BPC-157: A Review of Published Research Literature

Introduction

Among the peptides that have generated sustained interest in the preclinical research community, BPC-157 (Body Protection Compound-157) occupies a distinctive position. This synthetic pentadecapeptide (15-amino acid sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) is derived from a protein found in human gastric juice. The published literature on BPC-157, primarily from the laboratory of Predrag Sikiric and colleagues at the University of Zagreb, constitutes a substantial body of preclinical data that merits systematic review.

Origin and Characterization

BPC-157 was first characterized as a fragment of a larger protein identified in human gastric juice. It is classified as a stable gastric pentadecapeptide, meaning it has been observed to maintain structural integrity in gastric juice conditions, unlike many peptides that are rapidly degraded in the gastrointestinal environment [ref1].

Key physicochemical properties include:

• Molecular weight: approximately 1419 Da
• Sequence: 15 amino acids, no known structural homologs in existing protein databases
• Stability: researchers have reported stability in gastric juice and at various pH conditions in in-vitro studies

Published Research Areas

Gastrointestinal Studies

The earliest and most extensive body of BPC-157 research pertains to gastrointestinal models. Sikiric et al. have published numerous studies examining BPC-157 in rat models of gastric lesions, intestinal anastomosis, and inflammatory bowel conditions. The concept of "organoprotection" has been a central theme in this work, with researchers proposing that BPC-157 interacts with multiple protective pathways simultaneously [ref2].

Musculoskeletal Models

Several published studies have examined BPC-157 in animal models involving tendons, ligaments, and muscle tissue. Researchers have reported observations in rat models of Achilles tendon transection, quadriceps muscle crush injury, and medial collateral ligament damage. These studies typically employed histological assessment and functional measurements to characterize outcomes.

Vascular Research

A smaller but notable subset of publications has examined BPC-157 in vascular models. Vukojevic et al. investigated BPC-157 in a rat model of inferior caval vein ligation, reporting observations related to thrombosis and vascular function parameters [ref3].

Nervous System Models

Published research has also examined BPC-157 in models relevant to peripheral nerve injury, with studies reporting histological and functional observations in rat sciatic nerve transection models.

Methodological Considerations

When evaluating the BPC-157 literature, researchers should consider several important factors:

• Research group concentration -- a substantial majority of BPC-157 publications originate from a single research group (Sikiric et al., University of Zagreb). Independent replication by other laboratories remains limited.
• Animal models -- virtually all published BPC-157 research has been conducted in rodent models (predominantly rats). No peer-reviewed human clinical trial data have been published as of this review.
• Route of administration -- studies have employed various administration routes (intraperitoneal, intragastric, local application), which may affect comparability across experiments.
• Concentration ranges -- published studies have used varying amounts across different models, making cross-study comparison challenging.
• Mechanism -- while several mechanistic hypotheses have been proposed (including interactions with the nitric oxide system, growth factor pathways, and the FAK-paxillin pathway), the precise molecular mechanism remains an area of active investigation.

Current Status of Research

As of early 2026, BPC-157 remains a preclinical research compound. The published literature, while extensive in terms of animal model data, has not yet been validated through the controlled clinical trial process. Researchers interested in BPC-157 should approach the literature with awareness of these limitations and design studies that contribute to independent verification of published findings.

Conclusion

BPC-157 represents a peptide with a substantial preclinical research literature, primarily focused on gastrointestinal, musculoskeletal, and vascular models in rodents. While the published data are suggestive of multiple biological activities, the concentration of research within a single laboratory and the absence of published human clinical trial data are important context for evaluating this body of work. All discussion of BPC-157 in this article is within a research-only context. Investigators should adhere to institutional guidelines and applicable regulations when working with this compound.